bit.bio Expands Executive Team with Appointment of Przemek Obloj as Chief Financial Officer
July 31 2024 - 2:00AM
Business Wire
bit.bio, the company coding human cells for novel cures and a
pioneer in the field of synthetic biology, today announces the
appointment of Przemek Obloj as Chief Financial Officer. Mr. Obloj
will oversee the company’s financial strategy, including
fundraising, and work closely with bit.bio’s Founder and CEO, Mark
Kotter, and the executive team to support bit.bio’s continued
growth and innovation.
“Przemek brings a wealth of finance experience across the health
and life sciences sectors,” said Mark Kotter, Founder and CEO of
bit.bio. “His impressive track record, entrepreneurial drive and
connectivity with preeminent investment firms globally make him
uniquely qualified to lead our financial strategy. Broadening our
executive team will allow us to execute our growth strategy, scale
our operations and advance our position as a global leader in cell
programming.”
Mr. Obloj joins bit.bio with two decades of financial and
investment experience, focusing in health, life sciences and
technology sectors across Europe and North America. Throughout his
career, he built two investment organisations, led growth and
buyout transactions with combined equity investment of $5 billion,
and was involved in over a dozen successful exits. Most recently,
he served as Managing Partner and CIO at a Swiss family office.
Prior to that, he was a Managing Director and Head of European
Private Equity at PSP Investments, a C$250 billion Canadian pension
manager. Earlier in his career, he worked at CVC Capital Partners,
EQT and McKinsey & Company.
“There are few truly indispensable companies in the world, and I
believe bit.bio is rapidly becoming one of them,” Obloj added.
“When I met Mark four years ago, bit.bio was just starting to
commercialise its breakthrough cell programming technology. Today,
the company is emerging as a global leader in creating and
manufacturing human cells with unmatched precision and scale,
enabling step change improvements in drug discovery, research and
ultimately cell therapies. We are on a path to making a positive
difference for millions of patients while building a highly
valuable business in the process. I am thrilled to join this
exceptional team and help build the company towards its full
potential.”
About bit.bio
bit.bio, a synthetic biology company, is democratising human
cells to advance biomedical research (SDG9) and enable
transformative treatments (SDG3). With Nobel Prize-winning science
underpinning our understanding of cell identity as defined by
unique combinations of transcription factors, our deterministic
cell programming technology, opti-ox, enables conversion of induced
pluripotent stem cells (iPSCs) into any desired human cell type in
a single step. This is achieved within days and at industrial
scale, while maintaining exceptional purity and consistency. We are
creating highly differentiated human cell products for research and
drug discovery (ioCells) and cell therapy (txCells).
Since spinning out from the University of Cambridge and
launching in 2016, we have raised approximately $200m from leading
investors, including Arch Venture, Blueyard Capital, Charles River
Laboratories, Foresite Capital, Milky Way, National Resilience, and
Tencent.
For more information, please visit: www.bit.bio
For information on bit.bio’s trademarks, visit
www.bit.bio/trademarks
LinkedIn: https://www.linkedin.com/company/bitbioltd/
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240731927334/en/
Chris Hempel Spark Public Relations chris.hempel@sparkpr.com
+1-775-813-0285